|
1. Biologie
|
|
|
|
1.1 Biologie - Gènes
|
|
|
|
|
|
|
|
2. Etiologie
|
|
|
|
2.5 Etiologie - Gènes
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
Is BMI the Best Measure for Obesity? [Cancer Research Catalyst]
|
|
|
|
|
|
Despite
its limitations, obesity as calculated by BMI has been causally linked
to 14 types of cancer. The underlying causes that link obesity and
cancer are not fully understood, yet several mechanisms have been
implicated in disease progression, as highlighted in a previous post on
this blog.
|
|
|
|
|
|
|
3. Prévention
|
|
|
5 ways research can help prevent cancer [Cancer Research UK]
|
|
|
|
|
|
We
found that around 4 in 10 cancer cases could be prevented by things
like not smoking, keeping a healthy weight, enjoying the sun safely and
cutting back on alcohol. But there are more sides to cancer prevention
research than just smoking and obesity. Here we look at some of them.
|
|
|
|
|
|
|
3.2 Prévention - Obésité
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.12 Biopsies liquides
|
|
|
Putting pathology back in the spotlight [PHG Foundation]
|
|
|
|
|
|
The
consolidation of genetic testing services in England into seven genomic
laboratory hubs will significantly alter the landscape of genetics
services – at this time of great change, it is vital that pathology does
not get left behind.
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.10 Immunothérapies - Fusions et acquisitions
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
Incyte, Merck Cancer Trial Failure Damages IDO Drugs’ Prospects [Xconomy]
|
|
|
|
|
|
The
concept of blocking IDO has drawn considerable interest to the new drug
class. In 2015, Bristol-Myers Squibb paid $800 million up front to
acquire a big piece of Flexus Biosciences, including its IDO drug. Last
week, San Francisco-based Tempest Therapeutics raised $70 million in
financing to back its IDO inhibitor, which executives say could have
advantages over the current slate of experimental IDO drugs.
|
|
|
|
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
Why do new medicines cost so much, and what can we do about it? [The Guardian]
|
|
|
|
|
|
They
estimate the health service could save £200m to £300m a year – maybe
more – by embracing the biosimilars coming along, which include a
version of the breast cancer drug trastuzumab, better known as
Herceptin. But campaigners say patients with cancers and other
life-threatening diseases who don’t have loads of money cannot just wait
for the patents to run out.
|
|
|
|
|
|
|
6.12 Ethique
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
Bioinformatics for Precision Cancer Medicine [ESMO]
|
|
|
|
|
|
The
article describes the workflow of a molecular tumour board and the
specific bioinformatics support that it requires, from the primary
analysis of raw molecular profiling data to the automatic generation of a
clinical report and its delivery to decision-making oncologists.
|
|
|
|
|
|
|
6.7.2 Applis
|
|
|